• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Abbott Expands its Pure Bliss™ Line of Infant Formulas to Include European-Made and Organic Products; Offers the First and Only Organic Liquid Formula Available at U.S. Retail Stores

    8/27/24 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABT alert in real time by email
    • Pure Bliss™ Organic and Pure Bliss Organic with A2 Milk infant formulas – both USDA-certified – are now part of the Pure Bliss by Similac® line that includes European-made Pure Bliss Irish Farms, which starts with fresh milk from cows in Ireland
    • Pure Bliss Organic in the 2-fluid ounce ready-to-feed bottle is the only USDA-certified organic liquid infant formula offered in select U.S. retail stores
    • Pure Bliss by Similac delivers a selection of organic or European-made infant formulas that provide gentle, complete nutrition and specifically sourced ingredients

    ABBOTT PARK, Ill., Aug. 27, 2024 /PRNewswire/ -- Abbott (NYSE:ABT) today announced the expansion of its Pure Bliss™ by Similac® line of organic, and European-made infant formulas that give parents a variety of products to meet specific formula preferences.

    Pure Bliss by Similac offers specific sourcing of ingredients – whether certified organic ingredients or exclusively sourced milk from Ireland. These formulas are backed by Abbott's near century of providing high-quality, complete infant nutrition inspired by breast milk.   

    "More parents today are looking for infant formulas with particular milk types, ingredients and formats," said Misha Pardubicka-Jenkins, vice president of Abbott's Pediatric Nutrition business. "With the Pure Bliss by Similac line, parents can find what they are looking for whether that's organic, A2 milk, European-made or liquid, ready-to-feed formulas for convenience – all from an established and trusted brand."

    The Pure Bliss line includes the following:

    • Pure Bliss by Similac Irish Farms infant formula offers complete nutrition that's easy for babies to digest. Made in Ireland, this infant formula starts with fresh milk sourced from Irish farms where cows feed in grassy pastures much of the year. Irish Farms formula is exclusively produced at Abbott's manufacturing facility in Ireland and is imported to the U.S.
    • Pure Bliss by Similac Organic infant formula is a nutritionally complete, USDA-certified organic formula that is easy to digest. This formula, available in powder, and 32-fluid ounce and 2-fluid ounce options, is the only USDA-certified organic liquid formula available in U.S. retail stores for added feeding convenience.
    • Pure Bliss by Similac Organic with A2 Milk infant formula is a USDA-certified organic formula using milk from select cows that produce A2 beta-caseini protein, which is naturally easy to digestii and more like the protein found in breast milk.

    Find Pure Bliss at Select Retailers

    Parents can find Pure Bliss by Similac infant formula products at Amazon, Target and Walmart. Check Similac.com's product locator for a store and product availability near you.

    Abbott Expands its Pure Bliss™ Line of Infant Formulas

    Backed by 100 Years of Research and Commitment to Quality

    With the availability of Pure Bliss formulas, Similac provides even more choices for families backed by a brand that invests in clinical research and product development to advance nutrition science for all babies. Today, Abbott offers infant formulas that support the most vulnerable infants, formulas for food allergies, formulas for sensitive tummies, formulas for dietary preferences, and our closest to breastmilk formula that has five HMOs for parents and caregivers who need or prefer formula. 

    About Abbott:

    Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries.

    Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.

    i As compared to A1 beta-casein protein.

    ii All beta-casein protein is naturally easy to digest.

    Abbott Logo

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/abbott-expands-its-pure-bliss-line-of-infant-formulas-to-include-european-made-and-organic-products-offers-the-first-and-only-organic-liquid-formula-available-at-us-retail-stores-302230843.html

    SOURCE Abbott

    Get the next $ABT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABT

    DatePrice TargetRatingAnalyst
    10/10/2025$145.00Buy
    The Benchmark Company
    7/18/2025$145.00Hold → Buy
    Jefferies
    6/16/2025$143.00Market Perform
    Leerink Partners
    10/8/2024$130.00Outperform
    Oppenheimer
    9/19/2024$131.00Overweight
    Piper Sandler
    7/30/2024Buy → Hold
    Edward Jones
    5/30/2024$121.00Buy
    Goldman
    7/21/2023Underperform → Peer Perform
    Wolfe Research
    More analyst ratings

    $ABT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    The Benchmark Company initiated coverage on Abbott Labs with a new price target

    The Benchmark Company initiated coverage of Abbott Labs with a rating of Buy and set a new price target of $145.00

    10/10/25 8:35:50 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott Labs upgraded by Jefferies with a new price target

    Jefferies upgraded Abbott Labs from Hold to Buy and set a new price target of $145.00

    7/18/25 7:54:43 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Abbott Labs with a new price target

    Leerink Partners initiated coverage of Abbott Labs with a rating of Market Perform and set a new price target of $143.00

    6/16/25 8:17:39 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Abbott expands access to Precision Oncology portfolio through integration with Flatiron's OncoEMR® platform

    Broadens access to Abbott's Precision Oncology tests across more than 1,600 community cancer care centers and 4,700 providers in Flatiron's North America network, helping accelerate informed treatment decisionsAllows oncologists to order tests and view results directly in the clinical workflowABBOTT PARK, Ill. and NEW YORK, March 30, 2026 /PRNewswire/ -- Abbott (NYSE:ABT), the global healthcare company, and Flatiron Health, a leading healthtech company advancing point-of-care solutions in oncology, today announced the integration of Abbott's comprehensive Precision Oncology portfolio into OncoEMR®, Flatiron's cloud-based Electronic Medical Record (EMR) platform. Through this integration, onc

    3/30/26 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott hosts conference call for first-quarter earnings

    ABBOTT PARK, Ill., March 26, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its first-quarter 2026 financial results on Thursday, April 16, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day.About Abbott: Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical

    3/26/26 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    John Stamos and Jodie Sweetin reunite for "The (Second) Talk" with Cologuard® tests, encouraging colon cancer screening

    Potentially awkward conversations and 90s nostalgia combine to drive accessible screening for adults 45+Learn more at Cologuard.com/TheTalkABBOTT PARK, Ill., March 24, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) today announced a new campaign encouraging people to stop avoiding awkward conversations about colorectal cancer. The company is reuniting beloved sitcom family members, John Stamos and Jodie Sweetin, for "The (Second) Talk" campaign – because when it comes to colon cancer screening, even adults need another trusted adult for advice."The (Second) Talk," brings back TV's favorite uncle and niece duo to spoof "the talk" for a nostalgic, sitcom-style skit to remind people that while colon ca

    3/24/26 8:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Stratton John G

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    4/2/26 5:31:52 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Roman Michael F

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    4/2/26 5:24:18 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Gonzalez Patricia Paola

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    4/2/26 5:15:44 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    SEC Filings

    View All

    SEC Form S-8 filed by Abbott Laboratories

    S-8 - ABBOTT LABORATORIES (0000001800) (Filer)

    3/23/26 5:30:42 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott Laboratories filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - ABBOTT LABORATORIES (0000001800) (Filer)

    3/23/26 8:54:17 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Abbott Laboratories

    DEFA14A - ABBOTT LABORATORIES (0000001800) (Filer)

    3/13/26 4:01:21 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Starks Daniel J bought $1,087,331 worth of Common shares without par value (10,000 units at $108.73), increasing direct ownership by 0.15% to 6,738,817 units (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    2/6/26 8:04:16 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHAIRMAN AND CEO Ford Robert B bought $2,013,967 worth of Common shares without par value (18,800 units at $107.13) (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    1/26/26 8:02:24 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 24, 2023 - FDA Approves New Therapy for Rare Form of Blood Cancers Called Myelodysplastic Syndromes

    For Immediate Release: October 24, 2023 Today, the U.S. Food and Drug Administration approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. This is the first targeted therapy approved for this indication. The agency also approved the Abbott RealTime

    10/24/23 3:52:17 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    Financials

    Live finance-specific insights

    View All

    Abbott hosts conference call for first-quarter earnings

    ABBOTT PARK, Ill., March 26, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its first-quarter 2026 financial results on Thursday, April 16, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day.About Abbott: Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical

    3/26/26 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott completes acquisition of Exact Sciences

    Establishes Abbott as a leader in fast-growing cancer screening and diagnostics segmentsAdvances Abbott's mission to make healthcare more accessible and give people more control over their healthABBOTT PARK, Ill., March 23, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) today announced it has completed the acquisition of Exact Sciences, establishing Abbott as a leader in fast-growing cancer screening and diagnostics segments and enabling the company to serve millions of additional people. "Abbott's global scale, track record of operational and commercial excellence and work with healthcare systems around the world will expand access to important tools for early cancer detection and personalized trea

    3/23/26 8:50:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott declares 409th consecutive quarterly dividend

    ABBOTT PARK, Ill., Feb. 20, 2026 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 63 cents per share. This marks the 409th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable May 15, 2026, to shareholders of record at the close of business on April 15, 2026.Abbott has increased its dividend payout for 54 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years.About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio o

    2/20/26 11:38:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    Leadership Updates

    Live Leadership Updates

    View All

    Abbott HeartMates Community Delivers Holiday Cheer in Hallmark Channel's New Movie "The More the Merrier"

    Movie to feature cameos from youth who have overcome significant heart health challenges and are part of the Abbott HeartMates community as well as professional football player and HeartMates ambassador Damar Hamlin "The More the Merrier" is the first Hallmark movie ever to include cameos from real-life individuals who have overcome cardiovascular challengesCharacter in the movie was inspired by Abbott HeartMates member Zeke Mankins, who has established a friendship with Hamlin through Hamlin's ambassador role for the HeartMates communityMovie premieres on Hallmark Channel on Nov. 28, 2025, during Hallmark's Merry Thanksgiving Weekend during "Countdown to Christmas"ABBOTT PARK, Ill., Nov. 4,

    11/4/25 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott and Real Madrid Kick Off Search to Empower Young Soccer Talent

    This summer, Abbott and Real Madrid are hosting tryouts across the U.S. to form the 'Abbott Dream Team'Tryout attendees will learn about health and sports nutrition, encouraging them to promote healthy habits and an active lifestyle in their communitiesEleven selected players will travel to Madrid, train at Real Madrid's world-class facilities, and be instructed by Real Madrid coachesAmerican soccer icon Clint Dempsey will mentor the athletes throughout their journeyABBOTT PARK, Ill., May 7, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) announced today the creation of the inaugural 'Abbott Dream Team.' The program will seek out talented soccer players from across the United States and give them a o

    5/7/25 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cagent Vascular Appoints Paul Wilson as Chief Commercial Officer to Drive Growth and Market Expansion

    Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the appointment of Paul Wilson as Chief Commercial Officer (CCO). In this role, Mr. Wilson will lead the company's commercial strategy, overseeing sales, marketing, clinical programming, and business development initiatives. His leadership will help expand awareness, accelerate growth, and strengthen market positioning of Cagent Vascular's proprietary serration balloon technology. Mr. Wilson brings many years of experience in the medical device industry, having held senior commercial leadership positions at Teleflex (NYSE:TFX) and Abbott (NYSE:ABT). With

    3/4/25 11:38:00 AM ET
    $ABT
    $TFX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $ABT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

    SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)

    2/13/24 4:55:58 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

    SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)

    2/9/23 10:54:50 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

    SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)

    2/9/22 3:15:56 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care